These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 8683243

  • 1. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
    Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J.
    J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
    [Abstract] [Full Text] [Related]

  • 2. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
    Rose PG.
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):83-9. PubMed ID: 8783673
    [Abstract] [Full Text] [Related]

  • 3. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD, Rothenberg ML, Sarosy GA, Steinberg SM, Adamo DO, Reed E, Ozols RF, Kohn EC.
    Cancer; 1998 Nov 01; 83(9):1980-8. PubMed ID: 9806657
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer].
    Pawlicki M, Rolski J, Wiczyńska B, Rychlik U.
    Ginekol Pol; 1998 Jul 01; 69(7):580-5. PubMed ID: 9810418
    [Abstract] [Full Text] [Related]

  • 8. [Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer].
    Heidenreich A, Marx FJ, Peters HJ.
    Urologe A; 1999 Nov 01; 38(6):586-91. PubMed ID: 10591805
    [Abstract] [Full Text] [Related]

  • 9. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V, Giles FJ.
    Haematologica; 1999 Nov 01; 84(11):1035-42. PubMed ID: 10553165
    [Abstract] [Full Text] [Related]

  • 10. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH, Kong BH, Zhang YZ, Yang XS, Wang LJ, Su SL, Jiang J, Cui BX, Wang B.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct 01; 42(10):683-7. PubMed ID: 18241544
    [Abstract] [Full Text] [Related]

  • 11. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
    Sastry J, Kellie SJ.
    Pediatr Hematol Oncol; 2005 Oct 01; 22(5):441-5. PubMed ID: 16020136
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
    Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P, Rosen LS.
    Cancer; 2002 Apr 15; 94(8):2174-9. PubMed ID: 12001114
    [Abstract] [Full Text] [Related]

  • 13. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S, Chewaskulyong B.
    J Med Assoc Thai; 2004 Oct 15; 87(10):1162-7. PubMed ID: 15560691
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E.
    Oncology; 1993 Nov 15; 50 Suppl 2():2-9. PubMed ID: 8233297
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.